<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3039">
  <stage>Registered</stage>
  <submitdate>4/01/2011</submitdate>
  <approvaldate>4/01/2011</approvaldate>
  <nctid>NCT01271166</nctid>
  <trial_identification>
    <studytitle>Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>CSTI571BAU14</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab

Experimental: Glivec®, modified FOLFOX, Avastin® - 


Treatment: drugs: Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumour response as assessed by CT scan and RESIST</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed, locally advanced, recurrent or metastatic colorectal cancer

          -  ECOG 0 or 1

          -  Measurable disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior first line therapy for advanced disease

          -  Significant bulk of metastatic disease or rapid progression

          -  If prior adjuvant therapy, relapse within 6 months of a 5-FU based regimen or 12
             months of an oxaliplatin based regimen

        Other protocol-defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Novarts Investigative Site - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of
      Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level
      in 3 patient cohorts. Additional cohorts will be enrolled, or dose levels opened, subject to
      the toxicities observed. Once the MTD has been determined the dose level below will be
      re-opened and extra patients, to a total of 15, will be enrolled.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01271166</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>